<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002818</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064976</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <secondary_id>MCV-MCC-9409-2CC</secondary_id>
    <secondary_id>VCU-FDR000637</secondary_id>
    <secondary_id>NCI-V96-0966</secondary_id>
    <nct_id>NCT00002818</nct_id>
  </id_info>
  <brief_title>High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies</brief_title>
  <official_title>Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Deoxycytidine may protect patients from the side effects of&#xD;
      high-dose cytarabine.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of high-dose cytarabine given with&#xD;
      deoxycytidine in treating patients who have refractory acute myelogenous leukemia or other&#xD;
      lymphoma or leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Estimate the lowest dose of deoxycytidine (dC) that can be given as a host&#xD;
      protective agent in conjunction with high dose cytarabine (HD ARA-C) in patients with&#xD;
      refractory acute myelogenous leukemia or other hematologic malignancies. II. Determine the&#xD;
      maximum tolerated dose and dose-limiting toxic effects of HD ARA-C/dC in these patients. III.&#xD;
      Characterize the pharmacokinetics of continuously administered HD ARA-C/dC in these patients.&#xD;
      IV. Characterize, when possible, the pharmacodynamics of HD ARA-C, dC, and their metabolites&#xD;
      in blasts obtained from leukemic patients participating in this trial. V. Recommend the&#xD;
      lowest possible dose of dC that can be given in combination with HD ARA-C in future phase II&#xD;
      trials.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive deoxycytidine IV over 120 hours.&#xD;
      Beginning 12 hours after initiation of deoxycytidine, patients receive high dose cytarabine&#xD;
      IV over 96 hours. Patients achieving complete response receive no further therapy. Patients&#xD;
      achieving partial response or initial complete response and subsequent relapse receive an&#xD;
      additional course of therapy. Cohorts of 3-6 patients receive escalating doses of&#xD;
      deoxycytidine and high dose cytarabine until the maximum tolerated dose (MTD) is determined.&#xD;
      The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose&#xD;
      limiting toxicities.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 24-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">February 2001</completion_date>
  <primary_completion_date type="Actual">February 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">15</enrollment>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deoxycytidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: One of the following histologically documented hematologic&#xD;
        malignancies: Acute myelogenous leukemia Failed or relapsed following conventional dose&#xD;
        chemotherapy (e.g., doxorubicin, cytarabine) or high dose cytarabine (HD ARA-C) Chronic&#xD;
        myelogenous leukemia in blast crisis that has failed at least 1 conventional antileukemic&#xD;
        regimen Acute lymphoblastic leukemia (ALL) that is relapsed following or initially&#xD;
        refractory to conventional therapy Failed at least 1 salvage regimen for ALL Disease&#xD;
        refractory to conventional HD ARA-C allowed Primarily refractory or relapsed Hodgkin's or&#xD;
        non-Hodgkin's lymphoma Failed at least 1 conventional second or third generation regimen&#xD;
        (e.g., ProMACE-CytaBOM) Refractory multiple myeloma Not eligible for protocols of higher&#xD;
        priority and no alternative forms of therapy available that offer a reasonable chance of&#xD;
        palliation or cure&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% Life&#xD;
        expectancy: At least 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 3&#xD;
        mg/dL Renal: Creatinine clearance at least 40 mL/min Pulmonary: Pulse oximetry greater than&#xD;
        88% in patients with a history of pulmonary disease Other: No major concurrent disease that&#xD;
        renders patient a poor medical risk No uncontrolled infection Disease related fever allowed&#xD;
        at investigator's discretion No mental incapacity that precludes informed consent No&#xD;
        incarcerated patients Not pregnant Effective contraception required of fertile women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Not specified Biologic therapy: Not specified Chemotherapy: At&#xD;
        least 3 weeks since prior chemotherapy (24 hours since hydroxyurea) and recovered Endocrine&#xD;
        therapy: Not specified Radiotherapy: No prior radiotherapy to 30% or more of bone marrow At&#xD;
        least 4 weeks since prior radiotherapy and recovered Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

